Rho-associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 12, 2015, Pages 7560-7567

  Okumura, Naoki ^a   Okazaki, Yugo ^a   Inoue, Ryota ^a   Nakano, Shinichiro ^a   Fullwood, Nigel J ^b   Kinoshita, Shigeru ^c   Koizumi, Noriko ^a  

^a DOSHISHA UNIVERSITY   (Japan)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Corneal endothelial cells; Ripasudil; ROCK inhibitor

Indexed keywords

ACTIN; LIPOCORTIN 5; NERVE CELL ADHESION MOLECULE; PROTEIN ZO1; RIPASUDIL; EYE DROPS; ISOQUINOLINE DERIVATIVE; K-115; RHO KINASE; SULFONAMIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CORNEA ENDOTHELIUM; CORNEA THICKNESS; CORNEAL REFRACTIVE POWER; CORNEAL VOLUME; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SPECULAR MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; VISUAL SYSTEM PARAMETERS; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ELECTRON MICROSCOPY; FUCHS' ENDOTHELIAL DYSTROPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; RABBIT; ULTRASTRUCTURE;

ADULT; ANIMALS; ENDOTHELIUM, CORNEAL; FEMALE; FUCHS' ENDOTHELIAL DYSTROPHY; HUMANS; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RABBITS; RHO-ASSOCIATED KINASES; SULFONAMIDES;

EID: 84982740507     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17887     Document Type: Article

References (35)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90: 262-267.
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121: 2081-2090.
3. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130: 429-440.
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 701-713, discussion 829-830.
5. Tian B, Kaufman PL, Volberg T, Gabelt BT, Geiger B. H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol. 1998;116: 633-643.
6. Tian B, Gabelt BT, Peterson JA, Kiland JA, Kaufman PL. H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys. Invest Ophthalmol Vis Sci. 1999;40: 239-242.
7. Tian B, Sabanay I, Peterson JA, Hubbard WC, Geiger B, Kaufman PL. Acute effects of H-7 on ciliary epithelium and corneal endothelium in monkey eyes. Curr Eye Res. 2001;22: 109-120.
8. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42: 137-144.
9. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80: 197-206.
10. Koga T, Koga T, Awai M, Tsutsui J, Yue BY, Tanihara H. Rhoassociated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res. 2006;82: 362-370.
11. Kameda T, Inoue T, Inatani M, et al. The effect of Rhoassociated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53: 3092-3103.
12. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37: 1-12.
13. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42: 1029-1037.
14. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48: 3216-3222.
15. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74: 2211-2215.
16. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126: 309-315.
17. Inoue T, Tanihara H, Tokushige H, Araie M. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93: e393-e395.
18. Williams RD, Novack GD, van Haarlem T, Kopczynski C. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152: 834-841, e831.
19. Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39: 813-822.
20. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131: 1288-1295.
21. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156: 731-736.
22. Wato E, Omichi K, Yoneyama S, Tanaka M, Kagawa M, Amano Y. Safety evaluation of morphological changes in corneal endothelial cells induced by K-115 in cynomolgus monkeys. Fundam Toxicol Sci. 2014;1: 39-47.
23. Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379: 1749-1761.
24. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4: 446-456.
25. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3: 346-352.
26. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspasemediated activation of ROCK I. Nat Cell Biol. 2001;3: 339-345.
27. Blumenstein L, Ahmadian MR. Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation. J Biol Chem. 2004;279: 53419-53426.
28. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20: 242-248.
29. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med (Berl). 2007;85: 555-568.
30. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50: 17-24.
31. Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressurelowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93: e254-e260.
32. Lorenzetti DW, Uotila MH, Parikh N, Kaufman HE. Central cornea guttata. Incidence in the general population. Am J Ophthalmol. 1967;64: 1155-1158.
33. Zhang J, Patel DV. The pathophysiology of Fuchs’ endothelial dystrophy-a review of molecular and cellular insights. Exp Eye Res. 2015;130: 97-105.
34. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50: 3680-3687.
35. Birrell GB, Hedberg KK, Habliston DL, Griffith OH. Protein kinase C inhibitor H-7 alters the actin cytoskeleton of cultured cells. J Cell Physiol. 1989;141: 74-84.